The North America hepatitis B treatment market was valued at US$1.66 billion in 2024 and is projected to grow at a 6.9% CAGR, reaching US$3.01 billion by 2033, fueled by rising infection prevalence and expanded use of antivirals like tenofovir and entecavir alongside novel combination therapies https://www.datamintelligence.com/research-report/north-america-hepatitis-b-treatment-market